Serametrix
2236 Encinitas Boulevard
Encinitas
California
92024
United States
Tel: 760-652-4060
Fax: 760-652-4062
Website: http://www.serametrix.com/
9 articles about Serametrix
-
Caprion Biosciences expands its global biomarker and immune monitoring franchise by acquiring Serametrix Corporation
4/30/2019
Caprion Biosciences announced that the company acquired Serametrix Corporation, a specialized provider of immune monitoring services headquartered in Carlsbad, California.
-
Serametrix MDSC Assay Being Utilized By Infinity Pharmaceuticals in the First Clinical Study to Prospectively Identify Patients With High Blood Levels of MDSCs
5/22/2018
First Patient Enrolled in IPI-549 Plus OPDIVO® MDSC-High Cohort in Infinity Pharmaceuticals Ongoing IPI-549-01 Phase 1/1b Clinical Trial
-
ITUS and Serametrix Announce Results of a Blinded Prostate Cancer Study
3/27/2018
Prostate cancer study with Serametrix in which data from a previous collaboration between Serametrix and Memorial Sloan Kettering Cancer Center (MSK) was re-evaluated using ITUS technology.
-
Serametrix Gains CLIA Certification For MDSC-Based Blood Test For Predicting Response To Immunotherapy In Cancer Patients
9/29/2016
-
MDSC-based Blood Test For Predicting Response To Cancer Therapy Commercialized By Serametrix
11/19/2013
-
Penn State Hershey and Serametrix to Seek Companion Diagnostic for Immunotherapy in Pediatric Cancers
4/16/2012
-
OncoSec Medical Inc. and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies
11/16/2011
-
Serametrix Launches Test for Measuring Serum Antibodies to Leading Cancer Antigen NY-ESO-1
4/15/2010
-
Serametrix Partners with the Ludwig Institute For Cancer Research (LICR) to Develop and Commercialize Serum-Based Diagnostics
10/14/2009